Estudo para Avaliar a Segurança, Efeitos Farmacocinéticos e Farmacodinâmicos do MY006 em Voluntários Saudáveis e em Doentes com Alergia ao Amendoim
Um Estudo Randomizado, Quadruplamente Cego, Controlado por Placebo, de Dose Única Ascendente e Múltipla para Avaliar a Segurança, Tolerabilidade Local, Farmacocinética, Imunogenicidade, Farmacodinâmica e Atividade Clínica Exploratória do MY006 em Voluntários Saudáveis e em Pacientes Adolescentes e Adultos com Alergia ao Amendoim
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or two doses of MY006 or a placebo, administered by subcutaneous injection. The safety of MY006, including the number of adverse events, injection-site reactions, and immunogenicity, in these participants will be reviewed by an independent Safety Monitoring Committee and, if the safety is judged acceptable, the second part of the study will be started. In the second part of the study, adult and adolescent participants with peanut allergy receive one dose of MY006 or a placebo, administered by subcutaneous injection. Several weeks later, the participants are given a food peanut challenge to assess reactions and treatment effects. The duration of the study for participants is for up to 31 weeks.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72202
- Recrutamento
- Arkansas Children's Hospital and Research Institute
-
Contato:
- Erin Thomas
- Número de telefone: 501-364-2325
- E-mail: thomases@archildrens.org
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- Children's Hospital Colorado
-
Contato:
- David Fleischer
- Número de telefone: 720-777-2575
- E-mail: David.Fleischer@childrenscolorado.org
-
Colorado Springs, Colorado, Estados Unidos, 809907
- Recrutamento
- Asthma and Allergy Associates, PC
-
Contato:
- Kavya Muthyala
- Número de telefone: 719-473-8330
- E-mail: Kmuthyala@aacos.com
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Ativo, não recrutando
- Syneos Health Clinical Research Services LLC
-
Tampa, Florida, Estados Unidos, 33613
- Recrutamento
- University of South Florida
-
Contato:
- Catherine Smith
- Número de telefone: 813-631-4024
- E-mail: catherinesmith@usf.edu
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Massachusetts General Hospital
-
Contato:
- Brianna Fountain
- Número de telefone: 617-643-6772
- E-mail: blfountain@mgh.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48105
- Recrutamento
- Mary H. Weiser Food Allergy Center (MHWFAC) University of Michigan - Michigan Medicine
-
Contato:
- Ian Slack
- Número de telefone: 734-615-2592
- E-mail: Foodallergytrials@med.umich.edu
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Recrutamento
- Children's Health
-
Contato:
- Ruby Thapa
- Número de telefone: 214-648-0258
- E-mail: ruby.thapa@utsouthwestern.edu
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Texas Children's Hospital/Baylor College of Medicine
-
Contato:
- Daisy Vita
- Número de telefone: 832-824-3640
- E-mail: Dxtran1@texaschildrens.org
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
Part A - Single-ascending dose and multiple dose cohorts in healthy volunteers
- Subject is male or female between 18 to 55 years of age, inclusive, at the screening visit.
- Subject agrees voluntarily to participate, and is able to read and understand, and willing to sign, the Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to performing any screening visit procedures.
- Subject weight at screening and admission is between 45 kg and 100 kg, inclusive.
- Subject has a body mass index between 18.0 and 30.0 kg/m2, inclusive, at screening visit.
Part B - Peanut-allergic patient cohorts
-
Participant and/or parent/legal guardian must be able to understand and provide informed consent and/or assent, as applicable.
-
Patient is male or female between 12 to 55 years of age, inclusive, at the screening visit.
-
Patient weight at screening and admission is between 40 kg and 100 kg, inclusive.
-
If patient is 12-17 years of age, their body mass index (BMI) must be above the 5th percentile and below the 95th percentile for age and sex at the screening visit. If patient is 18 years of age or above, their BMI must be between 18.0 and 30.0 kg/m2, inclusive, at the screening visit.
-
Patient has a history of allergy to peanut and meets all of the following criteria:
- Positive skin prick test (≥5 mm wheal greater than Placebo) to peanut; and
- Positive specific IgE (≥0.7 kUA/L) to peanut and Ara h 2 at screening determined by ImmunoCap; and
- Positive double-blinded challenge to peanut during the screening period, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg of peanut protein.
-
Patient is willing and able to avoid peanut-containing products and any other allergy-inducing foods known to the patient for the duration of study participation.
Key Exclusion Criteria:
Part A - Single-ascending dose and multiple dose cohorts in healthy volunteers
-
Subject has a clinically relevant history, as determined by the Principal Investigator or designee, or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, and/or connective tissue diseases or disorders.
-
Subject has clinically significant abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:
- Systolic blood pressure ≥140 mmHg;
- Diastolic blood pressure ≥90 mmHg; and/or
- Heart rate ≥90 beats per minute.
-
Subject has any clinically significant abnormalities in rhythm, conduction, or morphology of the resting electrocardiogram (ECG) and/or any clinically significant abnormalities in the 12-lead ECG as considered by the Principal Investigator or designee that may interfere with the interpretation of QTc interval changes.
-
Subject has history of severe allergy/hypersensitivity, ongoing clinically significant allergy/hypersensitivity, as judged by the Principal Investigator or designee, known or suspected allergy to peanuts, and/or history of hypersensitivity to drugs with a similar structure or class.
Part B - Peanut-allergy patient cohorts
-
Patient has history of frequent or recent severe, life-threatening episodes of anaphylaxis or anaphylactic shock to peanut, as defined by more than 3 episodes of anaphylaxis within the past year and/or an episode of anaphylaxis within 60 days of screening.
-
Patient has uncontrolled or severe asthma/wheezing at screening, defined by one or more of the following criteria:
- Global Initiative for Asthma criteria regarding asthma control per latest guidelines;
- History of two or more systemic corticosteroid courses within 6 months of screening or one course of systemic corticosteroids within three months of screening to treat asthma/wheezing;
- Prior intubation/mechanical ventilation for asthma/wheezing;
- One hospitalization or emergency department visit for asthma/wheezing within 12 months of screening;
- Inhaled corticosteroid (ICS) dosing of >500 mcg daily fluticasone (or equivalent ICS based on the CoFAR Inhaled Corticosteroid Equivalency Tables); and/or
- Forced expiratory volume in one second (FEV1) <75% of predicted or FEV1/forced vital capacity <75%, with or without controller medications.
-
Patient has unstable exacerbated atopic disease (e.g., atopic dermatitis, urticaria, allergic rhinitis) defined by an episode of disease requiring initiation of systemic immunosuppressive or immunomodulatory treatment in the last 3 months.
-
Patient has current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal, or metabolic dysfunction unless currently controlled and stable as judged by the Principal Investigator.
-
Patient has abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:
- Systolic blood pressure ≥140 mmHg;
- Diastolic blood pressure ≥90 mmHg; and/or
- Heart rate ≥90 beats per minute.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Part A, Single Ascending Dose, Dose Level 1 (Healthy Volunteers)
Cohort A1: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
MY006 administered by subcutaneous injection. Placebo (vehicle) administered by subcutaneous injection. |
|
Experimental: Part A, Single Ascending Dose, Dose Level 2 (Healthy Volunteers)
Cohort A2: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
Experimental: Part A, Single Ascending Dose, Dose Level 3 (Healthy Volunteers)
Cohort A3: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
Experimental: Part A, Multiple Dose (Healthy Volunteers)
Cohort A4: MY006 or Placebo, subcutaneous, every 2 weeks, total of 2 doses in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
Experimental: Part B, Single Dose with Early Peanut Challenge (Peanut-Allergic Patients)
Cohort B1: MY006 or Placebo, subcutaneous, single dose in adults and adolescents. Peanut challenge will occur early after dosing. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
Experimental: Part B, Single Dose with Late Peanut Challenges (Peanut-Allergic Patients)
Cohort B2: MY006 or Placebo, subcutaneous, single dose in adults and adolescents. Peanut challenge will occur late after dosing. The cohort will consist of up to 16 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Subjects with Adverse Events and Serious Adverse Events (Safety and Local Tolerability)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
The nature of the adverse event (AE), date of the AE onset, date of the AE outcome to date, severity of the AE, and action taken for the AE will be documented together with the Principal Investigator's assessment of the seriousness of the AE and causal relationship to study drug and/or study procedure. The AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 21.0 or higher. |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetics: Cmax (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Maximum serum MY006 concentration in cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Pharmacokinetics: Tmax (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Time to reach Cmax of MY006 in cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Pharmacokinetics: AUClast (Part A, SAD, Cohorts A1-A3)
Prazo: From dosing (Day 1) to End of Study visit (Week 24)
|
Area under the concentration-time curve (AUC) from Pre-Dose (time 0) to the time of the last quantifiable concentration (tlast) in single ascending dose (SAD) cohorts of adult healthy volunteers (Part A) |
From dosing (Day 1) to End of Study visit (Week 24)
|
|
Pharmacokinetics: AUClast (Part A, MD, Cohort A4)
Prazo: From Day 15 to End of Study visit (Week 26)
|
AUC from Pre-Dose on Day 15 (time 0) to the time of the last quantifiable concentration (tlast) following last dose in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From Day 15 to End of Study visit (Week 26)
|
|
Pharmacokinetics: AUC0-504hr (Part A, SAD, Cohorts A1-A3)
Prazo: From dosing (Day 1) to Day 21
|
AUC from Pre-Dose (time 0) to 504 hours post-dosing in single ascending dose (SAD) cohorts of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 21
|
|
Pharmacokinetics: AUC0-336hr (Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to Day 14
|
AUC from Pre-Dose (time 0) to 336 hours postdosing in peanut-allergic patients (Part B) |
From dosing (Day 1) to Day 14
|
|
Pharmacokinetics: AUC0-336hr (Part A, MD, Cohort A4)
Prazo: From dosing (Day 1) to Day 14
|
AUC from Pre-Dose (time 0) to 336 hours post-dosing in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 14
|
|
Pharmacokinetics: AUCinf (Part A, SAD, Cohorts A1-A3; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Week 24)
|
AUC from Pre-Dose (time 0) extrapolated to infinite time in single ascending dose (SAD) cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Week 24)
|
|
Pharmacokinetics: AUCinf (Part A, MD, Cohort A4)
Prazo: From Day 15 to End of Study visit (Week 26)
|
AUC from Pre-Dose on Day 15 (time 0) extrapolated to infinite time in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From Day 15 to End of Study visit (Week 26)
|
|
Pharmacokinetics: AUC%extrap (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 24 or Week 26; Part B, Week 24)
|
Percentage of AUCinf that is due to extrapolation beyond tlast in cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or Week 26; Part B, Week 24)
|
|
Pharmacokinetics: λz (Part A, MD, Cohort A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Week 24)
|
Terminal elimination rate constant in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Week 24)
|
|
Pharmacokinetics: t½ (Part A, MD, Cohort A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
Terminal elimination half-life in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
|
Pharmacokinetics: CL/F (Part A, MD; Cohort A4, Day 15; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to Day 15 (Part A) or End of Study visit (Part B, Week 24)
|
Total body clearance in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to Day 15 (Part A) or End of Study visit (Part B, Week 24)
|
|
Pharmacokinetics: Vz/F (Part A, MD, Cohort A4, Day 15; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
Apparent volume of distribution in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
|
Pharmacokinetics: Racc,Cmax (Part A, MD, Cohort A4)
Prazo: From dosing (Day 1) to Day 15
|
Ratio of last dose Cmax (Day 15) to first dose Cmax (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 15
|
|
Pharmacokinetics: Racc,C72 (Part A; MD; Cohort A4)
Prazo: From dosing (Day 1) to Day 18
|
Ratio of MY006 concentration at 72 hours (C72) post Day 15 to first dose C72 (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 18
|
|
Pharmacokinetics: Racc,C168 (Part A, MD, Cohort A4)
Prazo: From Day 8 to Day 22
|
Ratio of MY006 concentration at 168 hours (C168) post Day 15 dose to first dose C168 (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From Day 8 to Day 22
|
|
Pharmacokinetics: Racc,AUC0-336hr (Part A, MD, Cohort A4)
Prazo: From dosing (Day 1) to Day 15
|
Ratio of last dose AUC0-336hr (Day 15) to first dose AUC0-336hr (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 15
|
|
Immunogenicity: ADA (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Percentage of subjects developing treatment-emergent anti-drug antibodies (ADA) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Immunogenicity: Treatment-enhanced ADA (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Percentage of subjects developing treatment-enhanced ADA |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Immunogenicity: ADA Titers (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Prazo: From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Amount of ADA in subjects |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- MY-CLN-SP-006-PA1001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .